Company profile

CHORD Therapeutics Sàrl

CHORD Therapeutics is dedicated to repurposing the small molecule drug CRD1, under orphan drug/orphan medicinal product designation, to bring a new effective therapy to patients with life-threatening and severely disabling neurological diseases.

Source: startup.ch

More news about CHORD Therapeutics Sàrl

20.12.2021 16:51

Merck acquires Chord Therapeutics

Financing

16.10.2020 08:28

Chord Therapeutics launches with USD 16 million Series A financing

Financing

CHORD Therapeutics Sàrl

Founded
2014

Kanton
GE

Principal

Innosuisse

Swiss Venture Capital Report

Swiss Venture Capital Report

The new Swiss Venture Capital Report provides a review of the whole of 2023. In addition to investments, the report will once again include the results of a survey of Swiss investors, an overview of venture capital fundraising and a list of exits. You can download the Report in our asset section.

Register for more services

Partners

Gebert Rüf Stiftung

Swiss Entrepreneurs Foundation

UBS

Contributors

EPFL Innovation Park Foundation

IFJ

Innovaud

Kendris

Lichtsteiner Foundation

SICTIC

Startup Campus

Swiss Economic Forum

Swisscom

Swissnex

Switzerland Innovation

venturelab

W.A. De Vigier Stiftung

Supporters

Basel Area Business & Innovation

Business Angels Switzerland

ESA BIC Switzerland

StartAngels Network

Switzerland Global Enterprise

Technology Fund

Technopark Luzern

Technopark Winterthur

TECHNOPARK Zürich

University of Basel

USI Startup Centre

Supporters

Basel Area Business & Innovation

Business Angels Switzerland

EPFL Innovation Park Foundation

ESA BIC Switzerland

Gebert Rüf Stiftung

StartAngels Network

Swiss Entrepreneurs Foundation

Switzerland Global Enterprise

Switzerland Innovation

Technology Fund

Technopark Luzern

Technopark Winterthur

TECHNOPARK Zürich

University of Basel

USI Startup Centre

W.A. De Vigier Stiftung

By continuing to use this website you agree with our TERMS AND CONDITIONS